Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 120

Results For "facility"

1652 News Found

Granules Pharmaceuticals receives ANDA approval for amphetamine mixed salts ER capsules
Drug Approval | January 25, 2023

Granules Pharmaceuticals receives ANDA approval for amphetamine mixed salts ER capsules

Granules now have a total of 53 ANDA approvals from USFDA


Fadnavis inaugurates 310-bed Medicover Hospitals in Navi Mumbai
Healthcare | January 25, 2023

Fadnavis inaugurates 310-bed Medicover Hospitals in Navi Mumbai

Medical Tourism will boost India’s economy


Gland Pharma’s Q3 FY23 revenue stood at Rs. 938 Cr with gross margin of 54%
News | January 24, 2023

Gland Pharma’s Q3 FY23 revenue stood at Rs. 938 Cr with gross margin of 54%

The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility


Syngene Q3FY23 revenue reaches Rs. 803 Cr; PAT reaches Rs. 110 Cr
News | January 24, 2023

Syngene Q3FY23 revenue reaches Rs. 803 Cr; PAT reaches Rs. 110 Cr

The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid


Briefs: Bafna Pharmaceuticals, Strides Pharma, IOL Chemicals and Pharmaceuticals and Krsnaa Diagnostics
News | January 21, 2023

Briefs: Bafna Pharmaceuticals, Strides Pharma, IOL Chemicals and Pharmaceuticals and Krsnaa Diagnostics

The National Institute of Pharmacy and Nutrition, Hungary has issued 'Certificate of GMP Compliance of Manufacturer' for IOL Chemicals and Pharmaceuticals Limited's products.


USFDA completes inspection at APL HealthCare
Drug Approval | January 19, 2023

USFDA completes inspection at APL HealthCare

The company has been issued ‘Form 483’ with two observations


Zydus receives tentative approval from USFDA for Levomilnacipran Extended-Release Capsules
Drug Approval | January 16, 2023

Zydus receives tentative approval from USFDA for Levomilnacipran Extended-Release Capsules

The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India


Zydus receives final approval and 180 days shared exclusivity from USFDA for Brexpiprazole tablets
Drug Approval | January 13, 2023

Zydus receives final approval and 180 days shared exclusivity from USFDA for Brexpiprazole tablets

Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults


Zydus receives final approval from the USFDA for Febuxostat Tablets
Drug Approval | January 10, 2023

Zydus receives final approval from the USFDA for Febuxostat Tablets

Febuxostat tablets had annual sales of USD 32 million in the United States according to IQVIA data (IQVIA MAT Sept. 2022).